Every year in the UK 65m urine specimens are analysed for diagnostic purposes; that’s 250,000 every working day. With an average mixed growth (contamination) rate of around 18%, up to 45,000 patients will not be accurately or promptly diagnosed today.
Like blood, urine is used for diagnosis and treatment that saves lives. Data gathered from every NHS Trust reveals that unreliable mixed growth rates vary from 0.38% to over 73%, wasting time, money … and jeopardising the health of the nation.
Clinically, urine is a window to patient health. A recent NHS Quality Improvement Audit shows that Peezy delivers 98.5% accuracy, making it the only specimen collection method to guarantee clinical diligence, hygiene, cost and efficiency savings.
“This is a cross-silo solution that can save time and money for the NHS.” Microbiology translational research manager, major London NHS Trust.
Quality Improvement Audit, Barts Health NHS Trust (interim results)
Professor Frank Chinegwundoh MHE, Consultant Urological Surgeon
The innovation role of Peezy Midstream within the NHS
James Barlow, Professor of Technology & Innovation Management, Imperial College Business School
“Urine analysis is as important clinically as blood testing, but rarely enjoys the same stringent sampling standards,” says Award-winning inventor of Peezy Midstream, Dr Vincent Forte. “Urine analysis is a vital diagnostic tool in many clinical areas. Hit-and-miss collection is unacceptable.”
Peezy: best practice for antenatal screening.
An accurate MSU can help identify pre-eclampsia, maternal diabetes, UTI and confirm the good health of mother and baby.